Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats

Marcelo N. Muscará, Fina Lovren, Webb McKnight, Michael Dicay, Piero Del Soldato, Christopher Triggle, John L. Wallace

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

1. Nonsteroidal anti-inflammatory drugs have been reported to exacerbate hypertension and to interfere with the effectiveness of some anti-hypertensive therapies. In this study, we tested the effects of a gastric-sparing, nitric oxide-releasing derivative of aspirin (NCX-4016) on hypertension in rats. 2. Hypertension was induced by administering L-NAME in the drinking water (400 mg l -1). Groups of rats were treated daily with aspirin, NCX-4016 or vehicle. 3. NCX-4016 significantly reduced blood pressure relative to the aspirin-treated group over the 2-week period of treatment. Aspirin and, to a lesser extent, NCX-4016 suppressed whole blood thromboxane synthesis. 4. In anaesthetized rats, acute intravenous administration of NCX-4016 caused a significant fall in mean arterial pressure in hypertensive rats, but was devoid of such effects in normotensive controls. 5. In vitro, NCX-4016 relaxed phenylephrine-pre-contracted aortic rings obtained from both normotensive and hypertensive rats, and significantly reduced their responsiveness to the contractile effects of phenylephrine. 6. These results suggest that NCX-4016 reduces blood pressure in hypertensive rats, not simply through the direct vasodilatory actions of the nitric oxide released by this compound, but also through possible interference with the effects of endogenous pressor agents. These properties, added to its anti-thrombotic effects, suggest that NCX-4016 may be a safer alternative to aspirin for use by hypertensive patients.

Original languageEnglish
Pages (from-to)1314-1322
Number of pages9
JournalBritish Journal of Pharmacology
Volume133
Issue number8
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Vasodilator Agents
Aspirin
Phenylephrine
Hypertension
Blood Pressure
nitroaspirin
Thromboxanes
NG-Nitroarginine Methyl Ester
Drinking Water
Intravenous Administration
Antihypertensive Agents
Stomach
Arterial Pressure
Nitric Oxide
Anti-Inflammatory Agents
Therapeutics
Pharmaceutical Preparations

Keywords

  • Anti-inflammatory
  • Blood pressure
  • Nitric oxide
  • Norepinephrine
  • Prostaglandin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Muscará, M. N., Lovren, F., McKnight, W., Dicay, M., Del Soldato, P., Triggle, C., & Wallace, J. L. (2001). Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. British Journal of Pharmacology, 133(8), 1314-1322.

Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. / Muscará, Marcelo N.; Lovren, Fina; McKnight, Webb; Dicay, Michael; Del Soldato, Piero; Triggle, Christopher; Wallace, John L.

In: British Journal of Pharmacology, Vol. 133, No. 8, 2001, p. 1314-1322.

Research output: Contribution to journalArticle

Muscará, MN, Lovren, F, McKnight, W, Dicay, M, Del Soldato, P, Triggle, C & Wallace, JL 2001, 'Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats', British Journal of Pharmacology, vol. 133, no. 8, pp. 1314-1322.
Muscará, Marcelo N. ; Lovren, Fina ; McKnight, Webb ; Dicay, Michael ; Del Soldato, Piero ; Triggle, Christopher ; Wallace, John L. / Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. In: British Journal of Pharmacology. 2001 ; Vol. 133, No. 8. pp. 1314-1322.
@article{1ca5f92c5dcb484187c6da75340033f3,
title = "Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats",
abstract = "1. Nonsteroidal anti-inflammatory drugs have been reported to exacerbate hypertension and to interfere with the effectiveness of some anti-hypertensive therapies. In this study, we tested the effects of a gastric-sparing, nitric oxide-releasing derivative of aspirin (NCX-4016) on hypertension in rats. 2. Hypertension was induced by administering L-NAME in the drinking water (400 mg l -1). Groups of rats were treated daily with aspirin, NCX-4016 or vehicle. 3. NCX-4016 significantly reduced blood pressure relative to the aspirin-treated group over the 2-week period of treatment. Aspirin and, to a lesser extent, NCX-4016 suppressed whole blood thromboxane synthesis. 4. In anaesthetized rats, acute intravenous administration of NCX-4016 caused a significant fall in mean arterial pressure in hypertensive rats, but was devoid of such effects in normotensive controls. 5. In vitro, NCX-4016 relaxed phenylephrine-pre-contracted aortic rings obtained from both normotensive and hypertensive rats, and significantly reduced their responsiveness to the contractile effects of phenylephrine. 6. These results suggest that NCX-4016 reduces blood pressure in hypertensive rats, not simply through the direct vasodilatory actions of the nitric oxide released by this compound, but also through possible interference with the effects of endogenous pressor agents. These properties, added to its anti-thrombotic effects, suggest that NCX-4016 may be a safer alternative to aspirin for use by hypertensive patients.",
keywords = "Anti-inflammatory, Blood pressure, Nitric oxide, Norepinephrine, Prostaglandin",
author = "Muscar{\'a}, {Marcelo N.} and Fina Lovren and Webb McKnight and Michael Dicay and {Del Soldato}, Piero and Christopher Triggle and Wallace, {John L.}",
year = "2001",
language = "English",
volume = "133",
pages = "1314--1322",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats

AU - Muscará, Marcelo N.

AU - Lovren, Fina

AU - McKnight, Webb

AU - Dicay, Michael

AU - Del Soldato, Piero

AU - Triggle, Christopher

AU - Wallace, John L.

PY - 2001

Y1 - 2001

N2 - 1. Nonsteroidal anti-inflammatory drugs have been reported to exacerbate hypertension and to interfere with the effectiveness of some anti-hypertensive therapies. In this study, we tested the effects of a gastric-sparing, nitric oxide-releasing derivative of aspirin (NCX-4016) on hypertension in rats. 2. Hypertension was induced by administering L-NAME in the drinking water (400 mg l -1). Groups of rats were treated daily with aspirin, NCX-4016 or vehicle. 3. NCX-4016 significantly reduced blood pressure relative to the aspirin-treated group over the 2-week period of treatment. Aspirin and, to a lesser extent, NCX-4016 suppressed whole blood thromboxane synthesis. 4. In anaesthetized rats, acute intravenous administration of NCX-4016 caused a significant fall in mean arterial pressure in hypertensive rats, but was devoid of such effects in normotensive controls. 5. In vitro, NCX-4016 relaxed phenylephrine-pre-contracted aortic rings obtained from both normotensive and hypertensive rats, and significantly reduced their responsiveness to the contractile effects of phenylephrine. 6. These results suggest that NCX-4016 reduces blood pressure in hypertensive rats, not simply through the direct vasodilatory actions of the nitric oxide released by this compound, but also through possible interference with the effects of endogenous pressor agents. These properties, added to its anti-thrombotic effects, suggest that NCX-4016 may be a safer alternative to aspirin for use by hypertensive patients.

AB - 1. Nonsteroidal anti-inflammatory drugs have been reported to exacerbate hypertension and to interfere with the effectiveness of some anti-hypertensive therapies. In this study, we tested the effects of a gastric-sparing, nitric oxide-releasing derivative of aspirin (NCX-4016) on hypertension in rats. 2. Hypertension was induced by administering L-NAME in the drinking water (400 mg l -1). Groups of rats were treated daily with aspirin, NCX-4016 or vehicle. 3. NCX-4016 significantly reduced blood pressure relative to the aspirin-treated group over the 2-week period of treatment. Aspirin and, to a lesser extent, NCX-4016 suppressed whole blood thromboxane synthesis. 4. In anaesthetized rats, acute intravenous administration of NCX-4016 caused a significant fall in mean arterial pressure in hypertensive rats, but was devoid of such effects in normotensive controls. 5. In vitro, NCX-4016 relaxed phenylephrine-pre-contracted aortic rings obtained from both normotensive and hypertensive rats, and significantly reduced their responsiveness to the contractile effects of phenylephrine. 6. These results suggest that NCX-4016 reduces blood pressure in hypertensive rats, not simply through the direct vasodilatory actions of the nitric oxide released by this compound, but also through possible interference with the effects of endogenous pressor agents. These properties, added to its anti-thrombotic effects, suggest that NCX-4016 may be a safer alternative to aspirin for use by hypertensive patients.

KW - Anti-inflammatory

KW - Blood pressure

KW - Nitric oxide

KW - Norepinephrine

KW - Prostaglandin

UR - http://www.scopus.com/inward/record.url?scp=0034858876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034858876&partnerID=8YFLogxK

M3 - Article

C2 - 11498517

AN - SCOPUS:0034858876

VL - 133

SP - 1314

EP - 1322

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 8

ER -